1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,310 | 1,350 | 18:01 | |
| 1,300 | 1,350 | 18:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:50 | Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week, Says NanoViricides | 213 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / September 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces... ► Artikel lesen | |
| Mi | Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox Has Begun in DRC, Announces NanoViricides | 774 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / September 23, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that the Phase II Clinical Trial of the Company's Novel Broad-Spectrum Antiviral... ► Artikel lesen | |
| 15.09. | NanoViricides, Inc.: Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides | 1.118 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / September 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces... ► Artikel lesen | |
| 08.09. | NanoViricides: Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo | 975 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / September 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces... ► Artikel lesen | |
| 31.08. | While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles | 757 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / August 31, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 18.08. | NanoViricides: The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon | 1.234 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 10.08. | NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak | 10.910 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 30.07. | NANOVIRICIDES, INC. - 8-K, Current Report | 9 | SEC Filings | ||
| 28.07. | NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial | 9.194 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 24.07. | NanoViricides announces $3.8M registered direct offering; shares down | 5 | Seeking Alpha | ||
| 24.07. | NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering | 1.507 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 24, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 22.07. | As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola | 8.903 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 22, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 17.07. | NANOVIRICIDES, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 13.07. | As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo | 757 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 08.07. | Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily | 851 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, reports that a... ► Artikel lesen | |
| 06.07. | Noble Capital startet Coverage für NanoViricides mit "Outperform" | 3 | Investing.com Deutsch | ||
| 06.07. | Noble Capital initiates NanoViricides stock with Outperform rating | 3 | Investing.com | ||
| 06.07. | As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo | 686 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it... ► Artikel lesen | |
| 29.06. | NanoViricides: US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher | 916 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of... ► Artikel lesen | |
| 22.06. | NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo | 1.115 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today announced that it has shipped the NV-387 Oral Gummies Drug Product for a Phase II Clinical... ► Artikel lesen |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 18,900 | -2,88 % | EQS-News: Formycon AG: Formycon setzt Maßstäbe in der Biosimilar-Entwicklung: Wissenschaftliche Grundlagen des innovativen Entwicklungsprogramms für FYB206 im Fachjournal BioDrugs veröffentlicht | EQS-News: Formycon AG
/ Schlagwort(e): Wissenschaftl. Publikation
Formycon setzt Maßstäbe in der Biosimilar-Entwicklung: Wissenschaftliche Grundlagen des innovativen Entwicklungsprogramms... ► Artikel lesen | |
| CANATU | 6,000 | +4,53 % | Canatu Oyj: Canatu's Half-year financial report January-June 2026: A pivotal period - sharpening Canatu's path to scalable growth; updated 2026 outlook | Canatu Plc Company release 25 August 2026 at 9:00 am EEST
Canatu's Half-year financial report January-June 2026: A pivotal period - sharpening Canatu's path to scalable growth; updated 2026 outlook
This... ► Artikel lesen | |
| ONTO INNOVATION | 251,50 | -0,44 % | $1000 Invested In Onto Innovation 10 Years Ago Would Be Worth This Much Today | ||
| GAUZY | 5,960 | 0,00 % | GAUZY LTD: Gauzy Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal | TEL AVIV, Israel, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Gauzy Ltd. (Nasdaq: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control technologies, today announced receipt of a delisting... ► Artikel lesen | |
| VEECO INSTRUMENTS | 43,460 | -0,32 % | Veeco Instruments pushes higher by 9%, adding to recent upswing | ||
| GOMSPACE | 0,998 | +0,05 % | GOMSPACE GROUP AB: GomSpace joins ESA-funded study for future Arctic satellite constellation supporting secure maritime communication | ||
| NVE | 94,50 | -1,56 % | Dividendenbekanntmachungen (03.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERISERV FINANCIAL INC US03074A1025 0,03 USD 0,026 EUR BF SPA IT0005187460 - 0,038 EUR CITIZENS & NORTHERN CORPORATION US1729221069 0... ► Artikel lesen | |
| NANOVEU | 0,039 | +95,00 % | NANOVEU LIMITED: Spinoff Signs MOU with NovaPeak to Assess METRON Integration | ||
| SOLESENCE | 0,810 | -2,41 % | Solésence, Inc.: Solésence Reports Second Quarter 2026 Financial Results | Quarterly Report Filed on Form 10-Q Company to Host Conference Call at 5:00 p.m. ET Today ROMEOVILLE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically... ► Artikel lesen | |
| KOPIN | 4,238 | 0,00 % | Stifel reiterates Kopin stock Buy rating on drone demand outlook | ||
| OBDUCAT | 0,034 | 0,00 % | NGM MARKET NOTICE: #26-72 Decision by the Disciplinary Committee regarding Obducat AB (publ) | ||
| ACACIA RESEARCH | 3,660 | -1,08 % | ACACIA RESEARCH CORP - 10-Q, Quarterly Report | ||
| ADVANCE ZINCTEK | 0,342 | -3,93 % | Advance Zinctek Ltd Profit Advances In Full Year | ||
| LAMPETIA | 0,156 | 0,00 % | EQS-Adhoc: Lampetia AG: Einigung über die Beendigung von Rechtsstreitigkeiten | EQS-Ad-hoc: Lampetia AG / Schlagwort(e): Sonstiges
Lampetia AG: Einigung über die Beendigung von Rechtsstreitigkeiten
16.07.2026 / 22:00 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| RIBER | 9,060 | 0,00 % | Riber Reports Improved Results For The First Half Of 2026 | RIBER REPORTS IMPROVED RESULTS FOR THE FIRST HALF OF 2026 Revenues of €12.7m (+19%) and gross margin of €5.1m (+31%), representing 39.8% of revenuesPositive net income of €0.2m, compared with -€0.8m... ► Artikel lesen |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Die relative Kursveränderung beträgt aktuell +0,79 % bei einem Aktienkurs von 1,270 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.